• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

June 8-9, 2010 Meeting of the Tobacco Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee Meeting Announcement

Date:  June 8, 2010 & June 9, 2010
Time:  8:30 a.m. – 5:00 p.m.
8:00 a.m. – 5:00 p.m.
Location: Holiday Inn, The Ballrooms
2 Montgomery Village Avenue
Gaithersburg, Maryland 20879.
Hotel phone number is 301-948-8900.

 

Agenda

On June 8-9, 2010, the subcommittee will receive presentations and discuss the development of a list of harmful or potentially harmful constituents, including smoke constituents, in tobacco products. Topics for discussion will include the criteria for selection of the constituents, developing a proposed list of harmful or potentially harmful constituents, the rationale for including each constituent, and the acceptable analytical methods for assessing the quantity of each constituent. A second meeting of this subcommittee, to continue these discussions as necessary, and to include ancillary and normalization standards for the constituents, will be scheduled for the summer of 2010.

 

Meeting Materials

Links to meeting materials will be added as they become available. FDA intends to make the complete background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

 

View Briefing Material

 

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

  • Written submissions may be made to the contact person on or before May 28, 2010.
  • Oral presentations from the public will be scheduled between approximately 2:45 p.m. and 3:45 p.m., June 8, 2010. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 20, 2010.

Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 21, 2010.

 

Contact Information

  • Karen M. Templeton-Somers, Ph.D.
    Center for Tobacco Products
    Food and Drug Administration
    9200 Corporate Boulevard
    Rockville, MD 20850

    Phone: 1-877-287-1373 (choose Option 4)
    FAX: 240-276-3904
    Email: TPSAC@fda.hhs.gov
  • FDA Advisory Committee Information Line
    1-800-741-8138
    (301-443-0572 in the Washington DC area)
    Code: 8732110002
    Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Website and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Karen Templeton-Somers at 1-877-287-1373 (choose Option 4) or TPSAC@fda.hhs.gov at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/default.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).